AARD Aardvark Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why AARD matters now
Aardvark Therapeutics, Inc. Common Stock (AARD) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.60 with +52.00% on the session and $165.8M in market capitalization; recent performance reads 1-month -10.07% and YTD -70.07%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-21.6M, and EPS of $-0.99. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -72.0%.
The latest indexable market news headline is "Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $20.50; recent insider activity includes Lee Tien-Li filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.99
P/S
0.00
EV/EBITDA
-0.34
DCF Value
$2.06
FCF Yield
-72.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.7%
ROA
-70.9%
ROIC
-85.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-21.6M | $-0.99 |
| Q4 2025 | $0.00 | $-17.6M | $-0.81 |
| FY 2025 | $0.00 | $-57.6M | $-2.64 |
| Q3 2025 | $0.00 | $-16.3M | $-0.75 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$22.75
Target (Median)
$20.50
Target Range
$3.00 - $47.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
4.47
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.